Abstract 4124
Background
Lung cancer is one of the most fatal cancer types globally. Currently, the immune status in the tumor microenvironment (TME) is highly valued. The immune status includes the expression of checkpoint molecules, co-stimulatory molecules, tumor-infiltrated lymphocyte status and TCR signal status, etc., which harbor different mechanisms in regulating the immune cells in the TME. However, the expression status of some biomarkers may have inner statistical characteristics, which may leave clues to the immune status and related clinical outcomes. In this study, a panel of 9 immune biomarkers was selected for the possible prediction of clinical outcomes in early stage resectable NSCLC.
Methods
Immunohistochemistry (IHC) was performed on surgical samples from 139 patients with NSCLC. Cox regression analysis and subgroup analysis of OS and RFS were conducted for the screening of biomarkers. The Principle Component Analysis (PCA) was conducted on screened biomarkers, including factorial analysis, principle component regression and principle component ranking. A database search was performed in order to verify the clinical characteristics. An Artificial Neuron Network analysis was established for the prediction of clinical outcomes.
Results
6 out of 9 biomarkers are considered significant and were selected for the data analysis. The KMO-Bartlett’s Sphericity test is valid (0.658>0.5, p = 0.0001). The principle component regression results indicate the OS is correlated with the principle component Z4(Y = 0.316×Z4 + 2.298, R = 0.189, p = 0.026). Also, the PFS also correlated with the principle component Z4 and Z2 (Y = 0.314×Z4 + 0.255×Z2 + 2.061, R = 0.249, p = 0.013). Principle components ranking (PCrank) is calculated and after the determination of cutoff 0.2, the intergroup comparison of subgrouphigh and subgrouplow is significant in OS (p = 0.025). Database searching validates our results. The ANN model successfully predicts the clinical outcome, with the testing accuracy of 94.1% and 96.2% in models 1 and 2, respectively.
Conclusions
The selected immunological panel has promising potential in predicting the prognosis of resectable NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported in part by a grant from National Natural Science Foundation of China (81802255), Shanghai Pujiang Program (17PJD036) and a grant from Shanghai Municipal Commission of Health and Family Planning Program (20174Y0131). National key research & development project (2016YFC0902300). Major disease clinical skills enhancement program of three year action plan for promoting clinical skills and clinical innovation in municipal hospitals, Shanghai Shen Kang Hospital Development Center Clinical Research Plan of SHDC (16CR1001A). The fundamental research funds for the central universities.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract